Stoke Therapeutics (STOK) Retained Earnings (2018 - 2026)
Stoke Therapeutics' quarterly Retained Earnings came in at -$115000.0 in Q1 2026, down 10.58% year-on-year from -$128602.2 in Q1 2025, and up 99.98% quarter-over-quarter from -$497.7 million in Q4 2025.
Stoke Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$115000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 10.58% year-over-year to -$115000.0; the trailing twelve-month figure through Mar 2026 stood at -$115000.0 (down 10.58% YoY), and the FY2025 full-year result was -$497.7 million, down 329512.58% from the prior year.
- Retained Earnings for Q1 2026 stood at -$115000.0, up from -$497.7 million in the prior quarter.
- The five-year high for Retained Earnings was $446000.0 in Q3 2025, with the low at -$497.7 million in Q4 2025.
- Average Retained Earnings over 5 years is -$166.8 million, with a median of -$1.3 million recorded in 2022.
- Year-over-year, Retained Earnings jumped 212.93% in 2024 and slumped 329512.58% in 2025.
- Tracing STOK's Retained Earnings over 5 years: stood at -$297.2 million in 2022, then tumbled by 35.23% to -$401.8 million in 2023, then surged by 99.96% to -$151000.0 in 2024, then tumbled by 329512.58% to -$497.7 million in 2025, then surged by 99.98% to -$115000.0 in 2026.
- The last three Retained Earnings figures came in at -$115000.0 (Q1 2026), -$497.7 million (Q4 2025), and $446000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -115,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115,000.00 |
| Dec 31, 2025 | -497.72 Mn |
| Sep 30, 2025 | 446,000.00 |
| Jun 30, 2025 | -401.43 Mn |
| Mar 31, 2025 | -104,000.00 |
| Dec 31, 2024 | -151,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | -453.92 Mn |
| Mar 31, 2024 | -428.22 Mn |
| Dec 31, 2023 | -401.85 Mn |
| Sep 30, 2023 | -147,000.00 |
| Jun 30, 2023 | -350.35 Mn |
| Mar 31, 2023 | -598,000.00 |
| Dec 31, 2022 | -297.15 Mn |
| Sep 30, 2022 | -1.70 Mn |
| Jun 30, 2022 | -1.28 Mn |
| Mar 31, 2022 | -684,000.00 |
| Dec 31, 2021 | -168,000.00 |
| Sep 30, 2021 | -22,000.00 |
| Jun 30, 2021 | -149.04 Mn |
| Mar 31, 2021 | -127.07 Mn |
| Dec 31, 2020 | -110.28 Mn |
| Sep 30, 2020 | -95.72 Mn |
| Jun 30, 2020 | -82.03 Mn |
| Mar 31, 2020 | -69.07 Mn |
| Dec 31, 2019 | -58.04 Mn |
| Sep 30, 2019 | -47.88 Mn |
| Jun 30, 2019 | -39.27 Mn |
| Dec 31, 2018 | -25.71 Mn |